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cardiac, renal and pulmonary disease). Inpatient and long-term
results suggest lower all cause mortality in the current population
compared to published trials. Preoperative staywas longer (2.8 vs.
1.9 days) in the retrospective data, while post-operative hospital
stay was shorter (6.4 vs. 6–8.4 days). Time spent in the operating
theater was 14–36% lower. Despite similar general (systemic) and
EVAR related complication rates, fewer patients required conver-
sion OR (0% vs. 1.5%) or re-interventions (10.1% vs. 15%).
CONCLUSION: Although this study was not comparative and
prospective, results indicate that, due to additional experience,
current EVAR procedures may have improved efﬁcacy, decreased
resource use and increased cost-effectiveness, compared with pub-
lished trials undertaken earlier in the uptake of EVAR.
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OBJECTIVES: Almost every individual will suffer an episode of
low back pain (LBP) that disrupts normal activities; however, 5%
of patients will experience severe pain and functional impairment
chronically. This group consumes approximately 90% of health
care costs for LBP, and the prognosis for recovery with non-
surgical management alone is poor. Current surgical preference is
spinal fusion (SF), which is being utilized with escalating fre-
quency. Intradiscal electrothermal therapy (IDET) is a minimally
invasive, less costly alternative to SF. This systematic review
compared clinical outcomes in patients undergoing IDET or SF
for discogenic LBP. METHODS: English-language articles pub-
lished from January 1995 through December 2006 were identi-
ﬁed through searching the PubMed database and bibliographies.
Articles were selected if disc degeneration or disruption was the
primary indication, and if follow-up outcome data included
evaluations of back pain severity, functional impairment and/or
quality of life. Data were extracted and summarized on patient
characteristics, surgical methods and clinical outcomes.
RESULTS: The search yielded 231 articles; 53 met stated criteria
(20 IDET, 33 SF). Overall, there were similar median percentage
improvements realized after IDET or SF, respectively, for 2 of the
3 outcomes evaluated: pain severity (52%, 50%), back function
(14%, 42%) and quality of life (43%, 46%). Perioperative com-
plications were common with SF (median: 14%) whereas adverse
events were rare with IDET (median: 0%). The median percent-
age of IDET patients experiencing a minimal clinically important
improvement in pain severity was 61%. CONCLUSION:
Patients with intractable discogenic LBP have a poor prognosis
for recovery with few treatment options. IDET offers a
minimally-invasive intermediate step in their continuum of care,
with symptom amelioration comparable to SF without the sur-
gical invasiveness, attendant complications and high costs. It may
be prudent to offer IDET prior to SF in carefully-selected patients
with deﬁnitive evidence of internal disc disruption.
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OBJECTIVES: Following the September 2006 agreement
between the Irish Pharmaceutical Healthcare Association (IPHA)
and Health Service Executive (HSE) pharmacoeconomic assess-
ment of technologies that may be of high cost or signiﬁcant
budget impact, may now be requested prior to reimbursement.
The aim of this paper is to describe the pharmacoeconomic
process in Ireland, currently conducted by the National Centre
for Pharmacoeconomics (NCPE). METHODS: The Department
of Health & Children (DoHC) determines which technologies
will be subject to pharmacoeconomic assessment. Following
notiﬁcation from the DoHC, a preliminary meeting between the
NCPE and the relevant pharmaceutical company is arranged, to
determine information requirements. Further meetings preceed
the submission of a formal cost-effectiveness evaluation. The
NCPE then prepares a report based on the company submission.
Finally, the company has an opportunity to review the NCPE
report, and if necessary, to appeal it. The report is then submitted
to the DoHC, where it can be used as an aid to the pricing and
reimbursement decision making process. The whole process must
take place within a 90 day period. RESULTS: Since the 2006
agreement, approximately 14 evaluations have been carried out
by the NCPE, four of which were full economic evaluations of
new drugs prior to reimbursement. The time from submission of
the NCPE report to reimbursement ranged from 1 to 2 months.
Two evaluations to inform public health policy were also con-
ducted (hepatitis B and pneumococcal conjugate vaccines).
CONCLUSION: Following recent developments, the demand
for pharmacoeconomic evaluation is set to increase. A major
strength of this process is the timeliness to the reimbursement
decision. The inﬂuence on public health interventions is already
evident, where both vaccination strategies have been adopted
into the routine infant immunisation programme. Evidence also
suggests that the evaluation process is having a positive impact
on prescribing in primary care.
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